GP
ENZY

GLG Partners’s Enzymotec Ltd ENZY Stock Holding History

GLG Partners’s Portfolio ENZY Stock Details ENZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-16,096
Closed -$184K – 549
2017
Q3 		$184K Buy
+16,096
New +$159K 0.01% 310

Other funds holding ENZY

PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
DG
Delek Group Herzliya, Israel $2.59B AUM 1.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
GH
GAM Holding Zurich, Switzerland $1.31B AUM 35.17% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return
CRA
Circle Road Advisors New York $27.7M AUM 35.85% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GLG Partners's ENZY Position: Q4 2017 in Review

GLG Partners sold out of Enzymotec Ltd (ENZY) in Q4 2017, closing a stake of 16,096 shares — an estimated $184K sold.

GLG Partners first reported a position in ENZY in Q3 2017 and held it in 1 quarter. The position peaked at $184K in Q3 2017. 37 funds tracked by Wall St. Rank hold ENZY as of Q4 2017.

  • GLG Partners reported no remaining Enzymotec Ltd position as of Q4 2017 after selling out during the quarter.
  • GLG Partners sold 16,096 Enzymotec Ltd shares in Q4 2017, an estimated $184K.
  • GLG Partners first reported a position in Enzymotec Ltd in Q3 2017 and held it in 1 quarter.
  • GLG Partners's Enzymotec Ltd position peaked at $184K in Q3 2017.
  • 37 funds tracked by Wall St. Rank held Enzymotec Ltd as of Q4 2017.

Based on GLG Partners's 13F filing for Q4 2017, filed 14 Feb 2018.